Thomas G. Gesner

729 total citations
16 papers, 602 citations indexed

About

Thomas G. Gesner is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Thomas G. Gesner has authored 16 papers receiving a total of 602 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 6 papers in Oncology and 5 papers in Immunology. Recurrent topics in Thomas G. Gesner's work include DNA Repair Mechanisms (3 papers), HER2/EGFR in Cancer Research (3 papers) and Microtubule and mitosis dynamics (2 papers). Thomas G. Gesner is often cited by papers focused on DNA Repair Mechanisms (3 papers), HER2/EGFR in Cancer Research (3 papers) and Microtubule and mitosis dynamics (2 papers). Thomas G. Gesner collaborates with scholars based in United States, Switzerland and Netherlands. Thomas G. Gesner's co-authors include R. Allan Mufson, David Bartos, Laurie B. Owen‐Schaub, Tucker W. LeBien, Carl F. Ware, Robert Radinsky, Laura S. Angelo, Bernhard Wörmann, Sylvia Ma and Steven C. Clark and has published in prestigious journals such as Blood, Clinical Cancer Research and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Thomas G. Gesner

16 papers receiving 571 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thomas G. Gesner United States 14 291 185 166 86 84 16 602
Laia Rosich Spain 15 410 1.4× 134 0.7× 121 0.7× 69 0.8× 29 0.3× 21 721
Jennifer M. Green United States 15 282 1.0× 55 0.3× 252 1.5× 134 1.6× 41 0.5× 24 728
Dominic Wall Australia 16 316 1.1× 340 1.8× 140 0.8× 130 1.5× 19 0.2× 39 729
Ami Miller United Kingdom 12 433 1.5× 143 0.8× 196 1.2× 71 0.8× 26 0.3× 23 747
Francesca Di Stefano United Kingdom 6 476 1.6× 212 1.1× 87 0.5× 35 0.4× 25 0.3× 12 679
Chad D. Walls United States 14 316 1.1× 123 0.7× 265 1.6× 78 0.9× 30 0.4× 24 705
Hannah J. Lomax-Browne United Kingdom 11 312 1.1× 106 0.6× 326 2.0× 130 1.5× 55 0.7× 15 752
William Riordan United States 9 300 1.0× 132 0.7× 120 0.7× 252 2.9× 21 0.3× 11 601
D. Paterson United Kingdom 3 178 0.6× 64 0.3× 191 1.2× 98 1.1× 29 0.3× 3 391
Meng Ling Choong Singapore 14 693 2.4× 168 0.9× 97 0.6× 265 3.1× 72 0.9× 24 1.0k

Countries citing papers authored by Thomas G. Gesner

Since Specialization
Citations

This map shows the geographic impact of Thomas G. Gesner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas G. Gesner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas G. Gesner more than expected).

Fields of papers citing papers by Thomas G. Gesner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas G. Gesner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas G. Gesner. The network helps show where Thomas G. Gesner may publish in the future.

Co-authorship network of co-authors of Thomas G. Gesner

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas G. Gesner. A scholar is included among the top collaborators of Thomas G. Gesner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas G. Gesner. Thomas G. Gesner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Karpov, Alexei S., Tinya J. Abrams, Joseph A. D’Alessio, et al.. (2018). Nicotinamide Phosphoribosyltransferase Inhibitor as a Novel Payload for Antibody–Drug Conjugates. ACS Medicinal Chemistry Letters. 9(8). 838–842. 29 indexed citations
2.
Bialucha, Carl Uli, Kathy L. Miller, Stuart W. Hicks, et al.. (2016). Microscale screening of antibody libraries as maytansinoid antibody-drug conjugates. mAbs. 8(3). 513–523. 17 indexed citations
3.
Wen, Quan, et al.. (2016). Miniaturized vortex-induced vibration energy harvester for low velocity air flow application. Fraunhofer-Publica (Fraunhofer-Gesellschaft). 1–3. 1 indexed citations
4.
Nikitin, Pavel A., Thomas G. Gesner, Yi-Chan Lin, et al.. (2016). In Vitro Characterization of Human Cytomegalovirus-Targeting Therapeutic Monoclonal Antibodies LJP538 and LJP539. Antimicrobial Agents and Chemotherapy. 60(8). 4961–4971. 24 indexed citations
5.
Lindvall, Mika, Christopher M. McBride, Thomas G. Gesner, et al.. (2011). 3D Pharmacophore Model-Assisted Discovery of Novel CDC7 Inhibitors. ACS Medicinal Chemistry Letters. 2(10). 720–723. 23 indexed citations
6.
Shafer, Cynthia M., Mika Lindvall, Cornelia Bellamacina, et al.. (2008). 4-(1H-Indazol-5-yl)-6-phenylpyrimidin-2(1H)-one analogs as potent CDC7 inhibitors. Bioorganic & Medicinal Chemistry Letters. 18(16). 4482–4485. 26 indexed citations
7.
Tse, Archie, Katherine G. Rendahl, Tahir Sheikh, et al.. (2007). CHIR-124, a Novel Potent Inhibitor of Chk1, Potentiates the Cytotoxicity of Topoisomerase I Poisons In vitro and In vivo. Clinical Cancer Research. 13(2). 591–602. 117 indexed citations
8.
McBride, Christopher M., Paul A. Renhowe, Thomas G. Gesner, et al.. (2006). 3-Benzimidazol-2-yl-1H-indazoles as potent c-ABL inhibitors. Bioorganic & Medicinal Chemistry Letters. 16(14). 3789–3792. 16 indexed citations
9.
Fanton, Christie, Michael W. Rowe, Edward J. Moler, et al.. (2006). Development of a Screening Assay for Surrogate Markers of Chk1 Inhibitor-Induced Cell Cycle Release. SLAS DISCOVERY. 11(7). 792–806. 4 indexed citations
10.
Ni, Zhi‐Jie, Paul A. Barsanti, Daniel J. Poon, et al.. (2006). 4-(Aminoalkylamino)-3-benzimidazole-quinolinones as potent CHK-1 inhibitors. Bioorganic & Medicinal Chemistry Letters. 16(12). 3121–3124. 58 indexed citations
11.
Bijl, Marc, Melanie Hart, L C Boeije, et al.. (1999). Patients with systemic lupus erythematosus with high plasma levels of sFas risk relapse.. PubMed. 26(1). 60–7. 20 indexed citations
12.
Owen‐Schaub, Laurie B., Laura S. Angelo, Robert Radinsky, et al.. (1995). Soluble Fas/APO-1 in tumor cells: a potential regulator of apoptosis?. Cancer Letters. 94(1). 1–8. 94 indexed citations
13.
Gesner, Thomas G., R. Allan Mufson, KJ Turner, & SC Clark. (1989). Identification through chemical cross-linking of distinct granulocyte- macrophage colony-stimulating factor and interleukin-3 receptors on myeloid leukemic cells, KG-1. Blood. 74(8). 2652–2656. 27 indexed citations
14.
Wörmann, Bernhard, Thomas G. Gesner, R. Allan Mufson, & Tucker W. LeBien. (1989). Proliferative effect of interleukin-3 on normal and leukemic human B cell precursors.. PubMed. 3(6). 399–404. 63 indexed citations
15.
Mazur, Eric Michael, Janet L. Cohen, R. Allan Mufson, et al.. (1988). Recombinant gibbon interleukin‐3 stimulates megakaryocyte colony growth in vitro from human peripheral blood progenitor cells. Journal of Cellular Physiology. 136(3). 439–446. 31 indexed citations
16.
Gesner, Thomas G., R. Allan Mufson, Christine R. Norton, et al.. (1988). Specific binding, internalization, and degradation of human recombinant interleukin‐3 by cells of the acute myelogenous, leukemia line, KG‐1. Journal of Cellular Physiology. 136(3). 493–499. 52 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Laia Rosich Breakdown of academic impact, for papers by Jennifer M. Green Breakdown of academic impact, for papers by Dominic Wall Breakdown of academic impact, for papers by Ami Miller Breakdown of academic impact, for papers by Francesca Di Stefano Breakdown of academic impact, for papers by Chad D. Walls Breakdown of academic impact, for papers by Hannah J. Lomax-Browne Breakdown of academic impact, for papers by William Riordan Breakdown of academic impact, for papers by D. Paterson Breakdown of academic impact, for papers by Meng Ling Choong
Rankless by CCL
2026